| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 风险提示：本次触发转股价格修正条件的期间从 2025 年 5 月 26 日起算，截 至 2025 年 6 月 9 日，益丰大药房连锁股份有限公司（以下简称"公司"、"本 公司"）股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计将触发 转股价格向下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决 定是否向下修正转股价格，并及时履行信息披露义务。敬请广大投资者注意投资 风险。 一、 "益丰转债"发行上市概况 经中国证券监督管理委员会证监许可[2024]109 号文同意注册，公司于 2024 年 3 月 4 日向不特定对象发行了 1,797.4320 万张可转换公司债券，每张面值 100 元，发行总额 179,743.20 万元。债券期限为发行之日起六年（自 2024 年 3 月 4 日至 2030 年 3 月 3 日），债券票面利率为：第一年 0.30%、第二年 0.50%、 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14]. - The pharmaceutical and biotechnology sector has shown a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18]. Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14]. - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15]. 2. Subsector Performance - The pharmaceutical sector's sub-indices all recorded gains, with the raw materials and blood products sectors leading with a 2.89% increase [7][22]. - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26]. 3. Recommended and Beneficiary Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihe Jiaye, among others [8]. - Beneficiary stocks identified are Shanhaishan, Yirui Technology, and Lianying Medical [27]. 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI applications in imaging and surgery [26]. - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29]. - **IVD Sector**: The report notes a 2.00% increase in the IVD sector, with a focus on AI-assisted diagnostics [30]. - **Blood Products**: The blood products sector is experiencing a 2.89% increase, with ongoing consolidation and product diversification [31]. - **Retail Pharmacy**: The offline pharmacy sector is expected to benefit from improved operational efficiencies through AI integration [34]. - **Healthcare Services**: The hospital sector has seen a 1.07% increase, with growth in specific medical fields like ophthalmology and reproductive health [36]. - **Traditional Chinese Medicine**: The sector is expected to recover as the impact of previous procurement policies diminishes [38]. - **CXO Sector**: The report indicates a positive outlook for the CXO sector, driven by increased demand for outsourcing in drug development [40].

Group 1 - The company will implement a cash dividend of RMB 0.40 per share (including tax) to all shareholders based on the total share capital registered on the dividend distribution date, without issuing bonus shares or capital reserve transfers [1][2] - The company's dividend payout ratio for 2024 will be 51.56%, considering the cash dividends already distributed in the first half of 2024 [1] - The convertible bonds "Yifeng Convertible Bonds" will suspend conversion from June 11, 2025, until the dividend distribution date, after which conversion will resume [2] Group 2 - The company will disclose the implementation announcement of the dividend distribution and the adjustment of the convertible bond conversion price on June 12, 2025 [2] - The total distribution amount will be adjusted if the conversion of the convertible bonds leads to a change in the company's total share capital, while maintaining the per-share distribution ratio [1][2] - The company has provided contact information for inquiries regarding the dividend distribution and convertible bonds [2]

| 证券代码：603939 | 证券简称：益丰药房 公告编号：2025-051 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 因益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）实施 2024 年 度权益分派,本公司的相关证券停牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113682 | 益丰转债 | 可转债转股停 | 2025/6/11 | | | | | | | 牌 | | | | | 注：停牌终止日及复牌日可在公司后续发布的"益丰转债"转股价格调整公告中查阅。 一、2024 年年度权益分派方案的基本情况 2025 年 5 月 29 日，公司 2024 年年度股东会审议通过了《关于 2024 年度利润分配预 案的议案》，决定以实施权益分派股权登记日登记的普通股总股本为基数，向全体股东每 股派发现金红利人民币 0.40 元（含税），不送红股，不进行资本公积金转增股本。叠加 2024 年中期已 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●被担保人名称：湖南九芝堂零售连锁有限公司（以下简称"九芝堂零售"）， 为益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）合并报表范 围内子公司。 ●对外担保的逾期累计数量：无 一、担保情况概述 1、担保基本情况及履行决策程序 公司于 2024 年 9 月 12 日召开的第五届董事会第七次会议与 2024 年 9 月 23 日召开的 2024 年第三次临时股东大会审议通过了《关于为子公司申请银行授信 提供担保的议案》。九芝堂零售因经营发展需要，向银行申请综合授信额度，公 司对其授信进行担保，新增担保总额合计 16,000.00 万元。 2、本次担保情况如下： 单位：万元 | 担保方 | 被担保方 | 担保 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：共赢智信汇率挂钩人民币结构性存款 A02288 期 （6,000.00 万），点金系列看涨两层区间 39 天结构性存款（1,000.00 万）。 赎回金额：7,000.00 万元 本次继续委托理财金额：6,000.00 万元 已履行的审议程序：经公司第五届董事会第十五次会议审议通过，同意在 确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情况下，使 用最高额度不超过 30,000.00 万元募集资金进行委托理财，用于购买安全性高、 流动性好的理财产品，自董事会审议通过起 12 个月有效，在上述额度与有效期 限内，购买理财产品资金可循环滚动使用。 特别风险提示 ...

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]

Group 1 - The annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. was held on May 29, 2025, in Changsha, Hunan Province [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, with a total of 9 directors and 3 supervisors present [3] Group 2 - All proposed resolutions were approved during the meeting, including the annual work reports of the board and supervisory committee, financial statements, and profit distribution plan for 2024 [4][5][6] - The meeting authorized the board to formulate a mid-term dividend plan and approved the appointment of an accounting firm for 2025 [5][6] - A significant resolution regarding the company's shareholder return plan for the next three years (2025-2027) was also passed [6] Group 3 - The meeting was witnessed by lawyers from Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting results were legally valid [6]

Core Viewpoint - The legal opinion confirms that the procedures for the 2024 annual shareholders' meeting of Yifeng Pharmacy Chain Co., Ltd. were conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [1][4][6]. Group 1: Meeting Procedures - The notice for the shareholders' meeting was announced on the designated media platform, detailing the time, location, voting methods, and agenda [3]. - The meeting took place on May 29, 2025, at 14:00 in Changsha, with both on-site and online voting options available for shareholders [3][4]. Group 2: Attendance and Qualifications - A total of 18 shareholders and their proxies attended the meeting in person, representing 657,188,892 shares, which is 54.2049% of the total shares [4][5]. - An additional 324 shareholders participated through online voting, representing a significant portion of the total shares [4]. Group 3: Voting Procedures and Results - The meeting utilized a combination of on-site and online voting, with a rigorous process for counting and monitoring votes, ensuring transparency [5][6]. - All proposals presented at the meeting received over 95% approval from the valid voting shares, indicating strong support from shareholders [6]. Group 4: Conclusion - The legal opinion concludes that the meeting's procedures, attendance qualifications, and voting results were all conducted in compliance with applicable laws and the company's articles of association [6].

Meeting Details - The shareholders' meeting was held on May 29, 2025, at Yifeng Pharmaceutical Logistics Park, Changsha, Hunan [1] - The meeting had a total attendance of 77.729% of the shares [1] Voting Results - All resolutions presented at the meeting were approved with overwhelming support from shareholders, with the highest approval rate being 99.9935% for one of the proposals [2][3] - The voting method combined both on-site and online participation, ensuring compliance with legal and regulatory requirements [1][3] Legal Compliance - The meeting's procedures, including the qualifications of attendees and the voting process, were confirmed to be in accordance with the Company Law and the company's articles of association [3]